Advertisement

Deferoxamine Mesylate Injection

[23 March 2016]

Products Affected - Description

All presentations are currently available

Reason for the Shortage

  • Fresenius Kabi has deferoxamine available.
  • Hospira has deferoxamine available.
  • Novartis discontinued Desferal 2 gram vials in 2015. The 500 mg vials are available.
  • Teva discontinued all deferoxamine presentations in 2013.
  • West-Ward discontinued deferoxamine in September 2014.
  • Watson discontinued all deferoxamine presentations.

Available Products

Desferal injection, Novartis
500 mg, vial, 4 count (NDC 00078-0467-91)
 
Deferoxamine injection, Fresenius Kabi
2 gram, vial, 1 count (NDC 63323-0599-30)
500 mg, vial, 1 count (NDC 63323-0597-10)
 
Deferoxamine injection, Hospira
2 gram, vial, 4 count (NDC 00409-2337-25)
500 mg, vial, 4 count (NDC 00409-2336-10)

Estimated Resupply Dates

All marketed presentations are available.

Related Shortages

Updated

March 23, January 20, 2016; December 3, November 17, September 25 and 2, August 4, July 20 and 10, May 8 and 6, March 23 and 13, February 24 and 4, January 14, 2015; December 15 and 3, October 24 and 8, September 3, August 8, July 14, 2014; August 5, May 17, March 11, February 5, January 7, 2013; December 10, November 27, October 22, September 27, August 3, June 5, April 23 and 4, March 20 and 8, February 16, January 25, 2012; December 22, October 27, September 20, August 25, June 30 and 2, May 11, March 17, January 24 and 6, 2011; December 3, November 9, October 11, September 28 and 8, August 24, 20 and 5, July 21 and 2, June 23, 2010, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement
ASHP Product Listing